PH12014500331A1 - Kinase inhibitor polymorphs - Google Patents
Kinase inhibitor polymorphsInfo
- Publication number
- PH12014500331A1 PH12014500331A1 PH1/2014/500331A PH12014500331A PH12014500331A1 PH 12014500331 A1 PH12014500331 A1 PH 12014500331A1 PH 12014500331 A PH12014500331 A PH 12014500331A PH 12014500331 A1 PH12014500331 A1 PH 12014500331A1
- Authority
- PH
- Philippines
- Prior art keywords
- kinase inhibitor
- polymorphs
- activity
- chemical compounds
- inhibitor polymorphs
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161522624P | 2011-08-11 | 2011-08-11 | |
| PCT/US2012/050453 WO2013023184A1 (en) | 2011-08-11 | 2012-08-10 | Kinase inhibitor polymorphs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014500331A1 true PH12014500331A1 (en) | 2014-03-31 |
Family
ID=47669006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2014/500331A PH12014500331A1 (en) | 2011-08-11 | 2012-08-10 | Kinase inhibitor polymorphs |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150065524A1 (enExample) |
| EP (1) | EP2741749A4 (enExample) |
| JP (1) | JP2014521726A (enExample) |
| KR (1) | KR20140079368A (enExample) |
| CN (1) | CN103957918A (enExample) |
| AU (1) | AU2012294202B2 (enExample) |
| BR (1) | BR112014003214A2 (enExample) |
| CA (1) | CA2844742A1 (enExample) |
| CL (1) | CL2014000343A1 (enExample) |
| CO (1) | CO6960542A2 (enExample) |
| CR (1) | CR20140082A (enExample) |
| DO (1) | DOP2014000027A (enExample) |
| EA (1) | EA027970B1 (enExample) |
| EC (1) | ECSP14013236A (enExample) |
| HK (1) | HK1199203A1 (enExample) |
| IL (1) | IL230850A0 (enExample) |
| MX (1) | MX2014001662A (enExample) |
| MY (1) | MY186267A (enExample) |
| PE (1) | PE20141358A1 (enExample) |
| PH (1) | PH12014500331A1 (enExample) |
| RU (1) | RU2636588C2 (enExample) |
| SG (2) | SG2014009492A (enExample) |
| TN (1) | TN2014000063A1 (enExample) |
| WO (1) | WO2013023184A1 (enExample) |
| ZA (1) | ZA201401211B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1747747B (zh) | 2003-01-06 | 2012-09-05 | 安吉奥开米公司 | 作为穿过血脑屏障的载体的抑酶肽及类似物 |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| RU2531591C2 (ru) | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
| US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| AU2010239069B2 (en) | 2009-04-20 | 2015-05-14 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog |
| MX2012000016A (es) | 2009-07-02 | 2012-03-26 | Angiochem Inc | Conjugados de peptidos multimericos y sus usos. |
| CN106924741A (zh) * | 2011-11-08 | 2017-07-07 | 因特利凯有限责任公司 | 使用多种药剂的治疗方案 |
| CN104250250A (zh) * | 2013-06-25 | 2014-12-31 | 苏州科捷生物医药有限公司 | 4-芳香胺基嘧啶类化合物及其抗肿瘤用途 |
| CN105899232A (zh) | 2013-11-13 | 2016-08-24 | 诺华股份有限公司 | 用于增强免疫应答的mTOR抑制剂 |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| IL322264A (en) | 2014-04-07 | 2025-09-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| ES2636646B1 (es) * | 2016-04-05 | 2018-08-03 | Universidade De Santiago De Compostela | NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs |
| CN109641947B (zh) | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| KR20190084310A (ko) | 2016-11-23 | 2019-07-16 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 살충제로서의 2-[3-(알킬술포닐)-2H-인다졸-2-일]-3H-이미다조[4,5-b]피리딘 유도체 및 유사한 화합물 |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| BR112020013794B1 (pt) * | 2018-01-09 | 2023-05-02 | Halcyon Labs Private Limited | Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| AU2012205669B2 (en) * | 2011-01-10 | 2015-08-20 | Infinity Pharmaceuticals Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
-
2012
- 2012-08-10 RU RU2014109023A patent/RU2636588C2/ru active
- 2012-08-10 PE PE2014000191A patent/PE20141358A1/es not_active Application Discontinuation
- 2012-08-10 WO PCT/US2012/050453 patent/WO2013023184A1/en not_active Ceased
- 2012-08-10 PH PH1/2014/500331A patent/PH12014500331A1/en unknown
- 2012-08-10 CN CN201280043863.6A patent/CN103957918A/zh active Pending
- 2012-08-10 EP EP12821708.0A patent/EP2741749A4/en not_active Withdrawn
- 2012-08-10 CA CA2844742A patent/CA2844742A1/en not_active Abandoned
- 2012-08-10 JP JP2014525188A patent/JP2014521726A/ja active Pending
- 2012-08-10 HK HK14112711.7A patent/HK1199203A1/xx unknown
- 2012-08-10 SG SG2014009492A patent/SG2014009492A/en unknown
- 2012-08-10 MX MX2014001662A patent/MX2014001662A/es unknown
- 2012-08-10 BR BR112014003214A patent/BR112014003214A2/pt not_active Application Discontinuation
- 2012-08-10 KR KR1020147006105A patent/KR20140079368A/ko not_active Ceased
- 2012-08-10 AU AU2012294202A patent/AU2012294202B2/en active Active
- 2012-08-10 MY MYPI2014000363A patent/MY186267A/en unknown
- 2012-08-10 SG SG10201606288TA patent/SG10201606288TA/en unknown
- 2012-08-10 EA EA201490446A patent/EA027970B1/ru not_active IP Right Cessation
- 2012-08-10 US US14/238,426 patent/US20150065524A1/en not_active Abandoned
-
2014
- 2014-02-06 IL IL230850A patent/IL230850A0/en unknown
- 2014-02-10 DO DO2014000027A patent/DOP2014000027A/es unknown
- 2014-02-11 CL CL2014000343A patent/CL2014000343A1/es unknown
- 2014-02-11 TN TNP2014000063A patent/TN2014000063A1/en unknown
- 2014-02-18 ZA ZA2014/01211A patent/ZA201401211B/en unknown
- 2014-02-20 CR CR20140082A patent/CR20140082A/es unknown
- 2014-03-11 EC ECSP14013236 patent/ECSP14013236A/es unknown
- 2014-03-11 CO CO14051879A patent/CO6960542A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ622208A (en) | 2016-04-29 |
| KR20140079368A (ko) | 2014-06-26 |
| PE20141358A1 (es) | 2014-10-12 |
| CR20140082A (es) | 2014-06-03 |
| TN2014000063A1 (en) | 2015-07-01 |
| WO2013023184A1 (en) | 2013-02-14 |
| MY186267A (en) | 2021-07-01 |
| AU2012294202A1 (en) | 2014-03-06 |
| AU2012294202B2 (en) | 2017-02-23 |
| CL2014000343A1 (es) | 2014-10-17 |
| ECSP14013236A (es) | 2014-06-30 |
| SG2014009492A (en) | 2014-09-26 |
| CA2844742A1 (en) | 2013-02-14 |
| EP2741749A4 (en) | 2015-04-15 |
| RU2014109023A (ru) | 2015-09-20 |
| MX2014001662A (es) | 2014-08-26 |
| DOP2014000027A (es) | 2014-07-15 |
| EA027970B1 (ru) | 2017-09-29 |
| JP2014521726A (ja) | 2014-08-28 |
| BR112014003214A2 (pt) | 2017-03-14 |
| CN103957918A (zh) | 2014-07-30 |
| IL230850A0 (en) | 2014-03-31 |
| EA201490446A1 (ru) | 2014-05-30 |
| CO6960542A2 (es) | 2014-05-30 |
| US20150065524A1 (en) | 2015-03-05 |
| HK1199203A1 (en) | 2015-06-26 |
| ZA201401211B (en) | 2015-12-23 |
| SG10201606288TA (en) | 2016-09-29 |
| RU2636588C2 (ru) | 2017-11-24 |
| EP2741749A1 (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000063A1 (en) | Kinase inhibitor polymorphs | |
| PH12018500960A1 (en) | Processes for preparing isoquinolinones and solid forms of isoquinolinones | |
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| EP2571357A4 (en) | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINAS MODULATION | |
| TN2012000071A1 (en) | Heterocyclic compounds and uses thereof | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| WO2012116237A3 (en) | Heterocyclic compounds and uses thereof | |
| PH12012502128B1 (en) | Chemical compounds | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| PH12013500975A1 (en) | Nampt and rock inhibitors | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| IN2015DN00827A (enExample) | ||
| MX343534B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| PH12015501920A1 (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS | |
| MX348311B (es) | Inhibidores nampt. | |
| MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| MX2014013758A (es) | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. | |
| MX2013005825A (es) | Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion. | |
| MX351961B (es) | Analogos de diazonamida. | |
| PH12012502137A1 (en) | Pyrimidinyl indole compounds | |
| MX2014002343A (es) | Inhibidores de parp. |